(Circulation. 2000;102:871.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Division of Medical Sciences (Cardiology), University of Birmingham (J.T., M.J.L., H.J.J., J.N.T.), and the Department of Nephrology, Queen Elizabeth Hospital (F.J.M., D.C.W.), Birmingham, UK.
Correspondence to Dr J. Thambyrajah, Department of Cardiovascular Medicine, University Hospital Birmingham NHS Trust, Birmingham B15 2TH, UK. E-mail J.Thambyrajah{at}bham.ac.uk
BackgroundConsiderable evidence suggests that hyperhomocysteinemia is an independent vascular risk factor that promotes atherosclerosis by inducing endothelial dysfunction. Although folic acid reduces hyperhomocysteinemia, the effect on adverse vascular events is unknown. We hypothesized that in patients with chronic renal failure, a condition associated with both hyperhomocysteinemia and atherosclerosis, treatment with folic acid would improve endothelial function.
Methods and ResultsIn a prospective, double-blind protocol, 100 patients (mean age 62 years, 67 men) with predialysis chronic renal failure were randomized to 5 mg folic acid or placebo daily for 12 weeks. Endothelial function was assessed by measuring (1) endothelium-dependent dilation of the brachial artery, (2) combined serum nitrite/nitrate concentrations, and (3) plasma von Willebrand factor concentration. Baseline characteristics of the 2 groups were similar. At the end of the study, both serum and red cell folate concentrations were greater in the folic acid group than the placebo group [mean (95% CI) 39.0 (29.8 to 51.0) versus 7.7 (6.6 to 8.9) µg/L and 739 (613 to 891) versus 220 (184 to 262) µg/L, respectively; both P<0.001]. Despite a reduction in hyperhomocysteinemia in the folic acid group compared with the placebo group [15.1 (14.1 to 16.2) versus 20.1 (18.2 to 22.2) µmol/L; P<0.001], there were no significant differences in endothelium-dependent dilation, combined serum nitrite/nitrate concentrations, or plasma von Willebrand factor concentration between the 2 groups.
ConclusionsHigh-dose folic acid lowers but fails to normalize hyperhomocysteinemia in patients with predialysis chronic renal failure. This was not accompanied by an improvement of endothelial function and suggests that treatment with folic acid may not reduce the burden of vascular disease in uremia.
Key Words: atherosclerosis endothelium kidney amino acids
This article has been cited by other articles:
![]() |
I. Baragetti, S. Raselli, A. Stucchi, V. Terraneo, S. Furiani, L. Buzzi, K. Garlaschelli, E. Alberghini, A. L. Catapano, and G. Buccianti Improvement of endothelial function in uraemic patients on peritoneal dialysis: a possible role for 5-MTHF administration Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3292 - 3297. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Pena, E. Wiltshire, R. Gent, L. Piotto, C. Hirte, and J. Couper Folic Acid Does Not Improve Endothelial Function in Obese Children and Adolescents Diabetes Care, August 1, 2007; 30(8): 2122 - 2127. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Anderson, Y.-H. Sun, J. Hubacek, M. E. Hyndman, S. Verma, L. Shewchuk, and N. Scott-Douglas Effects of folinic acid on forearm blood flow in patients with end-stage renal disease Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1927 - 1933. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Weiss, N. Ide, T. Abahji, L. Nill, C. Keller, and U. Hoffmann Aged Garlic Extract Improves Homocysteine-Induced Endothelial Dysfunction in Macro- and Microcirculation J. Nutr., March 1, 2006; 136(3): 750S - 754S. [Abstract] [Full Text] [PDF] |
||||
![]() |
Homocysteine Lowering Trialists' Collaboration Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials Am. J. Clinical Nutrition, October 1, 2005; 82(4): 806 - 812. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Fux, D. Kloor, M. Hermes, T. Rock, B. Proksch, A. Grenz, U. Delabar, R. Bucheler, S. Igel, K. Morike, et al. Effect of acute hyperhomocysteinemia on methylation potential of erythrocytes and on DNA methylation of lymphocytes in healthy male volunteers Am J Physiol Renal Physiol, October 1, 2005; 289(4): F786 - F792. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Vychytil, M. Fodinger, J. Pleiner, M. Mullner, P. Konner, S. Skoupy, C. Rohrer, M. Wolzt, and G. Sunder-Plassmann Acute effect of amino acid peritoneal dialysis solution on vascular function Am. J. Clinical Nutrition, November 1, 2003; 78(5): 1039 - 1045. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Stam, C. van Guldener, C. G. Schalkwijk, P. M. ter Wee, A. J. M. Donker, and C. D. A. Stehouwer Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity Nephrol. Dial. Transplant., May 1, 2003; 18(5): 892 - 898. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Vanholder, G. Glorieux, and N. Lameire Uraemic toxins and cardiovascular disease Nephrol. Dial. Transplant., March 1, 2003; 18(3): 463 - 466. [Full Text] [PDF] |
||||
![]() |
B. Bayes, M. C. Pastor, J. Bonal, J. Junca, J. M. Hernandez, N. Riutort, A. Foraster, and R. Romero Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients Nephrol. Dial. Transplant., January 1, 2003; 18(1): 106 - 112. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Weiss, C. Keller, U. Hoffmann, and J. Loscalzo Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia Vascular Medicine, August 1, 2002; 7(3): 227 - 239. [Abstract] [PDF] |
||||
![]() |
G. Buccianti, S. Raselli, I. Baragetti, F. Bamonti, E. Corghi, C. Novembrino, C. Patrosso, F. M. Maggi, and A. L. Catapano 5-methyltetrahydrofolate restores endothelial function in uraemic patients on convective haemodialysis Nephrol. Dial. Transplant., May 1, 2002; 17(5): 857 - 864. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.C. Verhaar, E. Stroes, and T.J. Rabelink Folates and Cardiovascular Disease Arterioscler Thromb Vasc Biol, January 1, 2002; 22(1): 6 - 13. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. FRIEDMAN, A. G. BOSTOM, J. SELHUB, A. S. LEVEY, and I. H. ROSENBERG The Kidney and Homocysteine Metabolism J. Am. Soc. Nephrol., October 1, 2001; 12(10): 2181 - 2189. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Thambyrajah, M. J. Landray, H. J. Jones, F. J. McGlynn, D. C. Wheeler, and J. N. Townend A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1858 - 1863. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A Brown and F. B Hu Dietary modulation of endothelial function: implications for cardiovascular disease Am. J. Clinical Nutrition, April 1, 2001; 73(4): 673 - 686. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Bennett-Richards, M. Kattenhorn, A. Donald, G. Oakley, Z. Varghese, L. Rees, and J.E. Deanfield Does Oral Folic Acid Lower Total Homocysteine Levels and Improve Endothelial Function in Children With Chronic Renal Failure? Circulation, April 16, 2002; 105(15): 1810 - 1815. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |